et al. A phase II study of the safety and efficacy of a novel oral FXa inhibitor (LY517717) for the prevention of venous thromboembolism following TKR or THR - Agnelli,G.; Haas,S.K.; Krueger,K.A. (J Thromb Haemost, 2007)